{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:37:13Z","timestamp":1769852233533,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T00:00:00Z","timestamp":1586044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T00:00:00Z","timestamp":1586044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["RSP-2019\/77"],"award-info":[{"award-number":["RSP-2019\/77"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Polycystic ovary syndrome (PCOS) is an endocrine disorder affecting about 10% of women in reproductive age and associated with a variety of hormonal abnormalities, including hyperandrogenemia and infertility, all of which could lead to PCOS. Statins were previously introduced as a therapeutic option for reducing testosterone levels in women with PCOS, either alone or in combination. The aim of this study is to evaluate the effectiveness of different statins alone or in combination with metformin in reducing testosterone levels in women with PCOS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Medline, Embase, and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link> were searched for studies that investigated the efficacy of statins, metformin, spironolactone, or combined oral contraceptives (COCs), individually or in combination, in reducing the testosterone level in patients with PCOS. The search was limited to randomized clinical trials and conducted according to the preferred reporting items for systematic reviews and meta-analyses - extension statement for network meta-analyses (PRISMA-NMA). The quality of included studies was assessed using the Cochrane Collaboration risk of bias (RoB) assessment tool. A frequentist network meta-analysis using random-effects models was used to assess the efficacy in reducing testosterone level and were expressed as odds ratios (OR) and 95% credible interval (95%Crl). All statistical analyses were performed using netmeta Version 1.0 on R statistical package.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Result<\/jats:title>\n<jats:p>Nine RCTs involving 613 patients were included. Atorvastatin showed greater reduction in testosterone level compared to COC (MD \u22122.78, 95%CrI \u22123.60, \u22121.97), spironolactone plus metformin (MD \u22122.83, 95%CrI \u22123.80, \u22121.87), simvastatin (MD \u22122.88, 95%CrI \u22123.85, \u22121.92), spironolactone (MD \u22122.90, 95%CI \u22123.77, \u22122.02), simvastatin plus metformin (MD \u22122.93, 95%CrI \u22123.79, \u22122.06), metformin (MD \u22122.97, 95%CrI \u22123.69, \u22122.25), lifestyle modification (MD \u22123.02, 95%CrI \u22123.87, \u22122.18), and placebo (MD \u22123.04, 95%CrI \u22123.56, \u22122.53).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Atorvastatin was found to be more effective than the other management strategies in reducing the total testosterone level for patients with PCOS. Future studies should focus on the optimal dose.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12905-020-00919-5","type":"journal-article","created":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T20:02:31Z","timestamp":1586116951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: a network meta-analysis of randomized clinical trials"],"prefix":"10.1186","volume":"20","author":[{"given":"Hussain H.","family":"Almalki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turki M.","family":"Alshibani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah A.","family":"Alhifany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar A.","family":"Almohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,5]]},"reference":[{"key":"919_CR1","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.fertnstert.2009.11.045","volume":"94","author":"T Kazerooni","year":"2010","unstructured":"Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril. 2010;94:2208\u201313. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.11.045.","journal-title":"Fertil Steril"},{"key":"919_CR2","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1210\/jc.2011-0501","volume":"96","author":"B Banaszewska","year":"2011","unstructured":"Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab. 2011;96:3493\u2013501. https:\/\/doi.org\/10.1210\/jc.2011-0501.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR3","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1210\/jc.2003-031780","volume":"89","author":"MA Ganie","year":"2004","unstructured":"Ganie MA, Khurana ML, Eunice M, Gulati M, Dwivedi SN, Ammini AC. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab. 2004;89:2756\u201362. https:\/\/doi.org\/10.1210\/jc.2003-031780.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR4","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1210\/jc.2008-0461","volume":"93","author":"K Hoeger","year":"2008","unstructured":"Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008;93:4299\u2013306. https:\/\/doi.org\/10.1210\/jc.2008-0461.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1210\/jc.2008-1750","volume":"94","author":"T Sathyapalan","year":"2009","unstructured":"Sathyapalan T, Kilpatrick ES, Coady A-M, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab. 2009;94:103\u20138. https:\/\/doi.org\/10.1210\/jc.2008-1750.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR6","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.fertnstert.2009.01.114","volume":"93","author":"D Romualdi","year":"2010","unstructured":"Romualdi D, Giuliani M, Cristello F, Fulghesu AM, Selvaggi L, Lanzone A, et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil Steril. 2010;93:2303\u201310. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.01.114.","journal-title":"Fertil Steril"},{"key":"919_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.fertnstert.2008.09.034","volume":"93","author":"HJ Teede","year":"2010","unstructured":"Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. Fertil Steril. 2010;93:184\u201391. https:\/\/doi.org\/10.1016\/j.fertnstert.2008.09.034.","journal-title":"Fertil Steril"},{"key":"919_CR8","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.fertnstert.2010.11.040","volume":"95","author":"N Raja-Khan","year":"2011","unstructured":"Raja-Khan N, Kunselman AR, Hogeman CS, Stetter CM, Demers LM, Legro RS. Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertil Steril. 2011;95:1849\u201352. https:\/\/doi.org\/10.1016\/j.fertnstert.2010.11.040.","journal-title":"Fertil Steril"},{"key":"919_CR9","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1210\/jc.2013-1040","volume":"98","author":"MA Ganie","year":"2013","unstructured":"Ganie MA, Khurana ML, Nisar S, Ahmed Shah P, Amin Shah Z, Kulshrestha B, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab. 2013;98:3599\u2013607. https:\/\/doi.org\/10.1210\/jc.2013-1040.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR10","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565\u201392. https:\/\/doi.org\/10.1210\/jc.2013-2350.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijgo.2009.04.022","volume":"107","author":"T Kazerooni","year":"2009","unstructured":"Kazerooni T, Ghaffarpasand F, Kazerooni Y, Kazerooni M, Setoodeh S. Short-term metformin treatment for clomiphene citrate\u2013resistant women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2009;107:50\u20133. https:\/\/doi.org\/10.1016\/j.ijgo.2009.04.022.","journal-title":"Int J Gynaecol Obstet"},{"key":"919_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1155\/2014\/468397","volume":"2014","author":"A Thabit","year":"2014","unstructured":"Thabit A, Alhifany A, Alsheikh R, Namnqani S, Al-Mohammadi A, Elmorsy S, et al. Effect of simvastatin and atorvastatin on serum vitamin D and bone mineral density in hypercholesterolemic patients: a cross-sectional study. J Osteoporos. 2014;2014:9. https:\/\/doi.org\/10.1155\/2014\/468397.","journal-title":"J Osteoporos"},{"key":"919_CR13","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1210\/jc.2009-1674","volume":"94","author":"B Banaszewska","year":"2009","unstructured":"Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab. 2009;94:4938\u201345. https:\/\/doi.org\/10.1210\/jc.2009-1674.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR14","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. London: The Cochrane Collaboration; 2011."},{"key":"919_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jrsm.1373","volume":"10","author":"RK Owen","year":"2019","unstructured":"Owen RK, Bradbury N, Xin Y, Cooper N, Sutton A. MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Synth Methods. 2019;10:569\u201381. https:\/\/doi.org\/10.1002\/jrsm.1373.","journal-title":"Res Synth Methods"},{"key":"919_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384. https:\/\/doi.org\/10.7326\/m14-2385.","journal-title":"Ann Intern Med"},{"key":"919_CR17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.12659\/MSM.914128","volume":"25","author":"S Yang","year":"2019","unstructured":"Yang S, Gu Y-Y, Jing F, Yu C-X, Guan Q-B. The effect of statins on levels of dehydroepiandrosterone (DHEA) in women with polycystic ovary syndrome: a systematic review and meta-analysis. Med Sci Monit. 2019;25:590\u20137. https:\/\/doi.org\/10.12659\/MSM.914128.","journal-title":"Med Sci Monit"},{"key":"919_CR18","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1210\/jc.2013-2674","volume":"98","author":"J Puurunen","year":"2013","unstructured":"Puurunen J, Piltonen T, Puukka K, Ruokonen A, Savolainen MJ, Bloigu R, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013;98:4798\u2013807. https:\/\/doi.org\/10.1210\/jc.2013-2674.","journal-title":"J Clin Endocrinol Metab"},{"key":"919_CR19","first-page":"165","volume":"10","author":"L Cassidy-Vu","year":"2016","unstructured":"Cassidy-Vu L, Joe E, Kirk JK. Role of statin drugs for polycystic ovary syndrome. J Family Reprod Health. 2016;10:165\u201375.","journal-title":"J Family Reprod Health"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-00919-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12905-020-00919-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-00919-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T23:03:35Z","timestamp":1617577415000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-020-00919-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,5]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1186\/s12905-020-00919-5","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,5]]},"assertion":[{"value":"25 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}